Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
Otonomy, Inc.May 11, 2021 GMT
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022
OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022
OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to be presented at ASGCT meeting; update on program to be provided in mid-2021
Recent financing extends cash runway into second half of 2023
Conference call and webcast today at 4:30 p.m. ET
Share:
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022
OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022
OTO-825 IND-enabling activities underway with preclinical proof-of-concept data to be presented at ASGCT meeting; update on program to be provided in mid-2021
Recent financing extends cash runway into second half of 2023
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended March 31, 2021 and provided an update on its product pipeline and corporate activities. The company will host a conference call and webcast today at 4:30 p.m. ET to discuss recent highlights and financial results.